U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Substance Class Protein
Created
by admin
on Sat Dec 16 03:07:42 GMT 2023
Edited
by admin
on Sat Dec 16 03:07:42 GMT 2023
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED RAT
Sequence Type UNKNOWN
Record UNII
KUW1QG1ZM3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SIPLIZUMAB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
siplizumab [INN]
Common Name English
MEDI-507
Code English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD2 (ANTIGEN)) (HUMAN-RAT MONOCLONAL MEDI-507 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-RAT MONOCLONAL MEDI-507 LIGHT CHAIN, DIMER
Common Name English
SIPLIZUMAB [USAN]
Common Name English
Siplizumab [WHO-DD]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD2 (ANTIGEN)) (HUMAN-RAT MONOCLONAL MEDI-507 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-RAT MONOCLONAL MEDI-507 LIGHT CHAIN, DIMER
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 170603
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
FDA ORPHAN DRUG 116498
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
EU-Orphan Drug EU/3/06/383
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
NCI_THESAURUS C20401
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
FDA ORPHAN DRUG 623917
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
FDA ORPHAN DRUG 107797
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
Code System Code Type Description
FDA UNII
KUW1QG1ZM3
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
PRIMARY
INN
8251
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
PRIMARY
EVMPD
SUB33504
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
PRIMARY
CAS
288392-69-8
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
PRIMARY
CHEMBL
CHEMBL2108742
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
PRIMARY
WIKIPEDIA
SIPLIZUMAB
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
PRIMARY
NCI_THESAURUS
C38685
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
PRIMARY
USAN
NN-38
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
PRIMARY
DRUG BANK
DB06371
Created by admin on Sat Dec 16 03:07:42 GMT 2023 , Edited by admin on Sat Dec 16 03:07:42 GMT 2023
PRIMARY
Related Record Type Details
CD2
CD2
TARGET -> INHIBITOR
Related Record Type Details
SIPLIZUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:ESTIMATE CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966